Specifically, RAF1 mutations were frequently observed in skin cutaneous melanoma (5.41%, 24/444) and uterine corpus endometrial carcinoma (4.54%, 24/529), whereas RAF1 amplification was highly concentrated in bladder tumors (10.71%, 44/411). This evidence concerns the gene RAF1 and cutaneous melanoma.